Healthtech firm Manus Neurodynamica has secured £2.6m to commercialise its neuromotor disorder diagnosis tool.
The Newcastle and Edinburgh-based firm has been supported by existing investors including the North East Innovation Fund, supported by the European Regional Development Fund, and managed by Northstar Ventures co-leading the round with Par Equity and involvement from SIS Ventures, Scottish Enterprise and Old College Capital. The funds will be used to help market its NeuroMotor Pen device which can support diagnosis and monitoring of neuromotor disorders including Parkinson's disease through measurement of fine motor skills.
Manus says the money will support its push into the EU pharmacy retail sector having already signed an agreement this month with Italian wellness firm Medispa to integrate the NeuroMotor Pen with its services. And funds will also support the firm's application for US FDA regulatory clearance and progressing its US trials.
